[go: up one dir, main page]

MX2018015032A - Composicion y metodo para reparacion y regeneracion muscular. - Google Patents

Composicion y metodo para reparacion y regeneracion muscular.

Info

Publication number
MX2018015032A
MX2018015032A MX2018015032A MX2018015032A MX2018015032A MX 2018015032 A MX2018015032 A MX 2018015032A MX 2018015032 A MX2018015032 A MX 2018015032A MX 2018015032 A MX2018015032 A MX 2018015032A MX 2018015032 A MX2018015032 A MX 2018015032A
Authority
MX
Mexico
Prior art keywords
rar
stem cells
regeneration
agonist
muscle
Prior art date
Application number
MX2018015032A
Other languages
English (en)
Inventor
Masahiro Iwamoto
Maurizio Pacifici
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45773490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018015032(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Jefferson filed Critical Univ Jefferson
Publication of MX2018015032A publication Critical patent/MX2018015032A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención proporciona métodos para reparación o regeneración muscular que comprenden administrar cantidades terapéuticamente efectivas de agonistas de RAR o células madre que se pretratan con el contacto con un agonista de RAR a un sujeto en un sitio de daño muscular. Adicionalmente, la invención proporciona composiciones que comprenden células madre tratadas con el agonista de RAR y métodos de uso de las células para reparación o regeneración muscular. En una modalidad, las células madre son células madre mesenquimales. En una modalidad, el agonista de RAR es un agonista de RAR?. En una modalidad, la administración del agonista de RAR se comienza durante un período de señalización retinoide endógena incrementada en el sujeto que resulta de la incurrencia o contracción del tejido muscular dañado.
MX2018015032A 2010-09-01 2013-02-26 Composicion y metodo para reparacion y regeneracion muscular. MX2018015032A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37899610P 2010-09-01 2010-09-01

Publications (1)

Publication Number Publication Date
MX2018015032A true MX2018015032A (es) 2021-12-08

Family

ID=45773490

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013002275A MX361414B (es) 2010-09-01 2011-08-31 Composición y método para reparación y regeneración muscular.
MX2018015032A MX2018015032A (es) 2010-09-01 2013-02-26 Composicion y metodo para reparacion y regeneracion muscular.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013002275A MX361414B (es) 2010-09-01 2011-08-31 Composición y método para reparación y regeneración muscular.

Country Status (20)

Country Link
US (6) US9789074B2 (es)
EP (3) EP2613776B1 (es)
JP (1) JP5986570B2 (es)
CN (2) CN103200937B (es)
AU (1) AU2011296080B2 (es)
BR (1) BR112013004685B1 (es)
CA (1) CA2809374C (es)
CL (1) CL2013000580A1 (es)
CO (1) CO6680694A2 (es)
DK (2) DK3721880T3 (es)
EA (1) EA026251B1 (es)
ES (3) ES2912593T3 (es)
HU (2) HUE051664T2 (es)
IL (1) IL224973B (es)
MX (2) MX361414B (es)
NZ (1) NZ607547A (es)
PL (2) PL2613776T3 (es)
PT (1) PT2613776T (es)
WO (1) WO2012030919A2 (es)
ZA (1) ZA201301536B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103200937B (zh) 2010-09-01 2020-07-03 托马斯杰弗逊大学 用于肌肉修复和再生的组合物和方法
US11026952B2 (en) 2011-06-16 2021-06-08 President And Fellows Of Harvard College Small molecules for mouse satellite cell proliferation
US9782417B2 (en) 2011-06-16 2017-10-10 Presidents And Fellows Of Harvard College Methods of increasing satellite cell proliferation with kinase inhibitors
US11963964B2 (en) 2011-06-16 2024-04-23 President And Fellows Of Harvard College Small molecules for mouse satellite cell proliferation
CN105188753B (zh) * 2012-11-08 2018-12-18 国立大学法人山口大学 角结膜病症的治疗剂
EP2943564A4 (en) * 2013-01-09 2016-10-26 Int Stem Cell Corp SMALL MOLECULES TO PROMOTE SKIN RECREATION
DK3000466T3 (en) * 2013-05-22 2018-11-26 Univ Yamaguchi INHIBITOR FOR RETINOCHOROIDAL DISEASES
US20170114019A1 (en) 2014-06-04 2017-04-27 Haro Pharmaceutical Inc. 18-20 member bi-polycyclic compounds
US9784665B1 (en) * 2014-12-29 2017-10-10 Flagship Biosciences, Inc. Methods for quantitative assessment of muscle fibers in muscular dystrophy
US11000057B2 (en) 2015-05-06 2021-05-11 University Of Southern California Fasting mimicking and enhancing diet for treating hypertension and lipid disorders
EP3091084A1 (en) * 2015-05-08 2016-11-09 Université Catholique De Louvain Methods for assessing the purity of a mesenchymal stem cells preparation
EP3411040A4 (en) * 2016-02-01 2020-07-29 President and Fellows of Harvard College SMALL MOLECULES FOR THE PROLIFERATION OF MOUSE SATELLITE CELLS
MX390115B (es) 2016-06-08 2025-03-20 Clementia Pharmaceuticals Inc Metodos para tratar la osificacion heterotopica.
JP7018957B2 (ja) 2016-11-16 2022-02-14 クレメンティア ファーマシューティカルズ インコーポレイテッド 多発性骨軟骨腫（ｍｏ）を処置するための方法
CA3019069A1 (en) * 2018-04-02 2019-10-02 Hubit Genomix, Inc. Prophylactic and/or therapeutic drug for diabetic nephropathy
US11135236B2 (en) * 2018-04-10 2021-10-05 Northwestern University Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity
GB201907647D0 (en) * 2019-05-30 2019-07-17 King S College London Therapeutic methods
FR3112684B1 (fr) * 2020-07-24 2022-08-12 Univ Grenoble Alpes Composés pour le traitement de l’hémophilie
CN116891497B (zh) * 2022-04-02 2025-12-16 上海旭成医药科技有限公司 视黄酸受体激动剂、其制备方法、中间体、药物组合物和应用
WO2023241717A1 (zh) * 2022-06-16 2023-12-21 中国科学院动物研究所 促进哺乳动物器官再生修复的物质及其应用

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS60500864A (ja) 1983-02-04 1985-06-06 ワドリ、テクナラジズ、インコーパレイティド 近縁関係にあるが別個のタンパク質間に存在する共通決定基に対して特異的なハイブリド−マ抗体の製造および特性づけ
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
JPS6253981A (ja) 1985-09-02 1987-03-09 Koichi Shiyudo 新規安息香酸誘導体
KR0139216B1 (ko) 1988-04-11 1998-05-01 제임스 엠. 캐내지 레티노이드 유사활성을 갖는 페놀 또는 벤조산의 테트랄린 에스테르
CA2129773C (en) 1993-09-02 2007-05-01 Michael Klaus Aromatic carboxylic acid derivatives
US5408002A (en) 1993-09-09 1995-04-18 Minnesota Mining And Manufacturing Company Azlactone-functional polymer blends, articles produced therefrom and methods for preparing both
US5498795A (en) 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5807900A (en) 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
US5624957A (en) 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
FR2739777B1 (fr) * 1995-10-11 1997-11-14 Cird Galderma Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
US5726191A (en) 1995-11-16 1998-03-10 Hoffmann-La Roche Inc. Aromatic carboxylic acid esters
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
FR2747041B1 (fr) 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
CA2288690A1 (en) * 1997-05-13 1998-11-19 Osiris Therapeutics, Inc. Osteoarthritis cartilage regeneration using human mesenchymal stem cells
US7514074B2 (en) * 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
DE69936720T2 (de) 1998-05-29 2008-04-30 Osiris Therapeutics, Inc. Menschliche cd45+ und/oder fibroblasten+ mesenchymale stammzellen
JP2002526445A (ja) 1998-09-24 2002-08-20 ブリストルーマイヤーズ スクイブ カンパニー ＲＡＲγ−特異的作用薬の活性エナンチオマー
JO2178B1 (en) 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of invasive diseases, using selected anti-PAR materials
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
WO2001068135A2 (en) 2000-03-14 2001-09-20 The University Of Western Ontario Compositions and methods for affecting osteogenesis
US20030211602A1 (en) 2000-04-28 2003-11-13 Anthony Atala Isolation of mesenchymal stem cells and use thereof
NZ524603A (en) 2000-10-02 2004-10-29 F New retinoids for the treatment of emphysema
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
WO2003024921A1 (en) 2001-09-18 2003-03-27 F. Hoffmann-La Roche Ag Alkyl urea retinoid agonists i
MXPA04002305A (es) 2001-09-18 2004-06-29 Hoffmann La Roche Agonistas ii de retinoides de urea sustituida.
AUPR892501A0 (en) * 2001-11-16 2001-12-13 Peter Maccallum Cancer Institute, The Method of enhancing self renewal of stem cells and uses thereof
US7592174B2 (en) 2002-05-31 2009-09-22 The Board Of Trustees Of The Leland Stanford Junior University Isolation of mesenchymal stem cells
EP1513803B1 (en) * 2002-06-04 2008-06-18 Galderma Research & Development Ligands that are inhibitors of the rar receptors
US20060035851A1 (en) * 2002-07-03 2006-02-16 Bianchi Marco E Use of hmgb1 in the treatment of tissue damage and or to promote tissue repair
JP2005532810A (ja) 2002-07-16 2005-11-04 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム 組織修復および組織形成のために間葉性幹細胞を移植する方法
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
SI2418220T1 (sl) 2003-12-10 2017-10-30 E. R. Squibb & Sons, L.L.C. Interferon alfa protitelesa in njihova uporaba
JP2005206544A (ja) * 2004-01-23 2005-08-04 Yasuyoshi Uchida 筋肉再生剤
AU2005240078A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
US7345931B2 (en) 2005-08-01 2008-03-18 Infineon Technologies Ag Maintaining internal voltages of an integrated circuit in response to a clocked standby mode
FR2894959B1 (fr) 2005-12-15 2008-02-29 Galderma Res & Dev Derives biphenyliques agonistes selectifs du recepteur rar-gamma
FR2894960B1 (fr) 2005-12-15 2008-02-29 Galderma Res & Dev Derives biphenyliques agonistes selectifs du recepteurs rar-gamma
CA2640484A1 (en) 2006-01-26 2007-08-09 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
ES2395401T3 (es) * 2006-03-23 2013-02-12 Tmrc Co., Ltd. kit para la terapia del cáncer y composición farmacéutica para la terapia del cáncer
BRPI0709886A2 (pt) 2006-03-31 2011-07-26 Hoffmann La Roche processo para a preparaÇço de compostos retinàides
CN101472572B (zh) 2006-05-16 2012-10-10 Io治疗有限责任公司 Rar拮抗剂或反向激动剂在治疗化学疗法和/或放射疗法副作用中的用途
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
JP5638961B2 (ja) 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
WO2010071583A1 (en) 2008-12-18 2010-06-24 Astrazeneca Ab Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient
US20120121546A1 (en) * 2009-02-05 2012-05-17 Vishal Bhasin Method of Producing Progenitor Cells from Differentiated Cells
WO2011011513A1 (en) 2009-07-21 2011-01-27 University Of Washington Through Its Center For Commercialization Inhibition of pathological bone formation
UA50725U (ru) * 2009-12-01 2010-06-25 Институт Нейрохирургии Им. Акад. А.П. Ромоданова Амн Украины Способ лечения больных с прогрессирующей мышечной дистрофией трансплантацией миобластов эмбриона человека
CN103200937B (zh) 2010-09-01 2020-07-03 托马斯杰弗逊大学 用于肌肉修复和再生的组合物和方法
CN103702967A (zh) 2011-03-14 2014-04-02 貝丝以色列女执事医疗中心 用于治疗增殖性病症的方法和组合物
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US20140220154A1 (en) 2011-07-01 2014-08-07 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Service Method of treating pathologic heterotopic ossification
US9458147B2 (en) 2012-02-22 2016-10-04 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as TNAP inhibitors
ES2660051T3 (es) 2012-09-28 2018-03-20 Vanderbilt University Compuestos heterocíclicos condensados como inhibidores selectivos de BMP
WO2014138088A1 (en) 2013-03-04 2014-09-12 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
US9682983B2 (en) 2013-03-14 2017-06-20 The Brigham And Women's Hospital, Inc. BMP inhibitors and methods of use thereof
DK3000466T3 (en) 2013-05-22 2018-11-26 Univ Yamaguchi INHIBITOR FOR RETINOCHOROIDAL DISEASES
EP3201187A4 (en) 2014-10-01 2018-04-11 The Brigham and Women's Hospital, Inc. Compositions and methods for inhibiting bmp
WO2017070194A1 (en) 2015-10-19 2017-04-27 The Children's Medical Center Corporation Method to inhibit endothelial-to-mesenchymal transition
EP3393474B1 (en) 2015-12-24 2023-07-19 The Regents of The University of Michigan Method of treating heterotopic ossification
MX390115B (es) 2016-06-08 2025-03-20 Clementia Pharmaceuticals Inc Metodos para tratar la osificacion heterotopica.
JP6630255B2 (ja) 2016-09-30 2020-01-15 株式会社沖データ 画像形成装置及び通信システム

Also Published As

Publication number Publication date
CN103200937A (zh) 2013-07-10
US12023312B2 (en) 2024-07-02
NZ607547A (en) 2015-06-26
ES2975123T3 (es) 2024-07-03
JP2013536855A (ja) 2013-09-26
ES2823234T3 (es) 2021-05-06
MX2013002275A (es) 2013-05-22
BR112013004685B1 (pt) 2021-09-21
PT2613776T (pt) 2020-10-21
CO6680694A2 (es) 2013-05-31
US9789074B2 (en) 2017-10-17
US20200069620A1 (en) 2020-03-05
BR112013004685A2 (pt) 2019-04-24
CN111773213A (zh) 2020-10-16
EP4066826C0 (en) 2024-03-06
AU2011296080A1 (en) 2013-03-14
CN111773213B (zh) 2023-02-24
US9314439B2 (en) 2016-04-19
EP2613776B1 (en) 2020-07-29
EA201370051A1 (ru) 2014-03-31
US20140303223A1 (en) 2014-10-09
CL2013000580A1 (es) 2013-07-12
WO2012030919A2 (en) 2012-03-08
JP5986570B2 (ja) 2016-09-06
US20230201146A1 (en) 2023-06-29
EP4066826A1 (en) 2022-10-05
US20140363402A1 (en) 2014-12-11
ZA201301536B (en) 2015-06-24
EP2613776A4 (en) 2014-03-12
EA026251B1 (ru) 2017-03-31
DK2613776T3 (da) 2020-10-19
US20250108022A1 (en) 2025-04-03
WO2012030919A3 (en) 2012-07-05
EP2613776A2 (en) 2013-07-17
US11433039B2 (en) 2022-09-06
MX361414B (es) 2018-12-05
AU2011296080B2 (en) 2014-12-04
US20180000762A1 (en) 2018-01-04
DK3721880T3 (da) 2022-05-09
ES2912593T3 (es) 2022-05-26
CA2809374C (en) 2021-02-23
US10292954B2 (en) 2019-05-21
PL3721880T3 (pl) 2022-05-23
EP3721880B1 (en) 2022-02-02
CN103200937B (zh) 2020-07-03
HUE059024T2 (hu) 2022-10-28
HUE051664T2 (hu) 2021-03-29
EP3721880A1 (en) 2020-10-14
IL224973B (en) 2018-06-28
EP4066826B1 (en) 2024-03-06
CA2809374A1 (en) 2012-03-08
PL2613776T3 (pl) 2021-01-11

Similar Documents

Publication Publication Date Title
MX2018015032A (es) Composicion y metodo para reparacion y regeneracion muscular.
GT201400043A (es) Imidazopiridazinas sustituidas con amino
MX383365B (es) Metodos para tratar inflamacion e hipertension con eliminadores de gama-cetoaldehidos.
CL2017002527A1 (es) Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares. (divisional de solicitud n°2485-2015).
CR20160200A (es) Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladores
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
CL2011002180A1 (es) Compuestos derivados de benzimidazol, inhibidores de mpges-1; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y dolor.
ES2572211T3 (es) Regeneración de músculo esquelético utilizando células madre mesenquimales
EA201291309A1 (ru) ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ, sGC АКТИВАТОРОВ, ОДНИХ И В КОМБИНАЦИИ С PDE5 ИНГИБИТОРАМИ, ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОГО СКЛЕРОЗА (SSc)
CL2011003160A1 (es) Compuestos derivados de heterociclicos, moduladores cb2; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades reumaticas, autoinmune, inflamatorias, dolor, entre otras.
AR089993A1 (es) Macrociclos peptidomimeticos
MX385122B (es) Uso de ibrutinib en el tramiento de enfermedad injerto contra huésped crónica.
CO7141430A2 (es) Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación
CL2013000342A1 (es) Combinaciones de a) un agonistas del receptor beta-3 adrenergico y b) antagonistas del receptor muscarinico para tratar vejiga hiperactiva; un metodo de tratamiento par ala vejiga hiperactiva que comprende la combinacion.
MX365321B (es) Métodos para el tratamiento de neutropenia mediante agonistas retinoides.
MX350719B (es) Composiciones de bakuchiol para el tratamiento de hiperpigmentacion post-inflamatoria.
MX362804B (es) Composiciones acuosas de capsaicinoides que comprenden un analgésico y un vehículo acuoso, y uso de las mismas para el tratamiento del dolor.
MX357510B (es) Metodos para tratar ataques de gota.
MX2018000657A (es) Agente estimulador del receptor 5-hidroxi triptamina 1b para usarse como un promotor de la autorrenovación y/o diferenciación de células satélite.
MX383944B (es) Composiciones para el cuidado personal.
CU20170086A7 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
MX2017011018A (es) Inhibicion de la actividad de olig2.
MX383502B (es) Métodos y composiciones para el tratamiento de úlceras gástricas